Scribe Therapeutics Inc. filed its Amended and Restated Certificate of Incorporation and Amended and Restated Bylaws, which became effective on July 27, 2026, in connection with the closing of its initial public offering. Scribe Therapeutics Inc. operates in the biotechnology industry and develops therapeutic solutions using gene editing technology.